Catalent today announced a collaboration with Johnson & Johnson for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.

Catalent today announced the completion of its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, Indiana facility.

Catalent today announced it will host a one day workshop titled, “Achieving Integrated Biologics Development: Challenges and How to Tackle Them”.

Catalent today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors.

Catalent, Inc. today announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.

Catalent and MaSTherCell Global, Inc. today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of $315 million in cash.

Catalent today welcomed the news that DiaMedica Therapeutics has received U.S. FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for chronic kidney disease.

Catalent today announced that Christopher Hepler, Manager, Catalent Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held on Jan 28 – 30, 2020.

Catalent today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, Catalent’s President and Chief Operating Officer.